Affordable Semaglutide Generics: A New Era for Weight Management in India

The recent expiration of the semaglutide patent has led to the introduction of affordable generics in India, potentially transforming weight management and diabetes care. With prices dropping significantly, experts are optimistic about the health benefits these medications could provide. However, concerns about quality, appropriate use, and potential side effects remain. This article explores the implications of these new generics, the current health crisis in India, and the necessary precautions for their use. As the market opens up, understanding the balance between accessibility and safety will be crucial for patients and healthcare providers alike.

By Narendra Chaudhary Mar 23, 2026, 17:11 IST

Introduction to Semaglutide Generics

The expiration of the patent for semaglutide, the key ingredient in well-known weight loss medications such as Ozempic and Wegovy, has opened the door for significantly cheaper generic alternatives in India, with prices dropping by as much as 90%. Experts have been consulted to evaluate whether these lower-cost versions will enhance health outcomes for Indians or if they will carry the same side effects observed with Ozempic.

Launch of Generic Semaglutide

On March 20, the patent held by Novo Nordisk, the original manufacturer of semaglutide, expired. Following this, NATCO Pharma introduced its generics, Semanat and Semafull, priced at INR 1,290 and INR 1,750 per month, respectively, which is significantly lower than Ozempic's INR 8,800 monthly cost. Eris Lifesciences also plans to launch a multi-dose vial named Sundae at a similar price point. Other companies like Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and Alkem Laboratories have also rolled out their versions of semaglutide. For instance, Dr. Reddy’s Obeda is available for INR 4,200 per month, while Sun Pharma offers Noveltreat starting at INR 900 and Sematrinity at INR 750. Glenmark’s GLIPIQ vials are priced between INR 325 and INR 440 weekly. Zydus Lifesciences has announced its generics under the names SEMAGLYNTM, MASHEMATM, and ALTERMET, with an average monthly treatment cost of around INR 2,200. Alkem Laboratories will market Semasize, Obesema, and Hepaglide starting at INR 450 weekly.

Potential Health Benefits

Dr. V. Mohan, Chairman of Dr. Mohan's Diabetes Specialities Centre in Chennai, described this development as “very positive” but emphasized the importance of maintaining quality. According to a BBC report, approximately 50 branded generics of semaglutide are expected to enter the Indian market soon. Semaglutide functions as a GLP-1 receptor agonist, mimicking the GLP-1 hormone to manage appetite and blood sugar levels. It slows gastric emptying, prolonging the feeling of fullness, reduces hunger signals to the brain, and prompts insulin release from the pancreas when blood sugar levels rise. Dr. Anoop Misra, leading the Fortis-C-DOC Centre for Diabetes and Endocrinology in Delhi, noted that for a nation like India, which faces a significant burden of Type 2 Diabetes and obesity, this could lead to substantial clinical improvements.

Current Health Crisis in India

India is grappling with a diabetes crisis, ranking second globally with around 101 million individuals diagnosed with diabetes and an additional 136 million classified as prediabetic, as per the ICMR-INDIAB study. The National Family Health Survey (NFHS) 2019–21 indicates that 24% of Indian women and 23% of men are either overweight or obese.

Evaluating Risks and Benefits

In individuals with type 2 diabetes, the body may resist insulin or fail to produce enough of it. GLP-1 agonists stimulate insulin release and suppress glucagon, while also acting on the brain to curb hunger and delaying stomach emptying, which can facilitate weight loss—an essential aspect of diabetes management. Semaglutide is not merely a glucose-lowering agent; it also aids in weight management and offers cardiovascular, liver, and kidney benefits. Increased availability could help mitigate long-term complications such as heart disease and kidney failure. If utilized correctly, this could represent a significant advancement in comprehensive metabolic care.

Affordability and Accessibility

Dr. Vivek Bindal, Senior Director & Head of Bariatric and Robotic Surgery at Max Healthcare, remarked that the enhanced affordability of GLP-1 receptor agonists is a double-edged sword. While it improves access for patients suffering from obesity, type 2 diabetes, and high cardiovascular risk—conditions prevalent in India—it also raises concerns about the potential for misuse. A recent study in The Lancet Psychiatry highlighted that Ozempic could also alleviate depression, anxiety, and self-harm in high-risk diabetic patients. However, the benefits hinge on proper prescribing, product quality, and patient monitoring.

Cautions and Recommendations

Dr. Mohan cautioned that these medications should only be prescribed by qualified healthcare professionals and used strictly for therapeutic purposes, not for cosmetic weight loss. He also called for vigilant monitoring of side effects and emphasized the need for more data from India and stringent pharmacovigilance. Experts warned against the potential for “indiscriminate or unsupervised use” due to lower costs, particularly for cosmetic weight loss without proper medical evaluation. Dr. Bindal reiterated that GLP-1 therapies are not quick solutions; they necessitate careful patient selection, dose adjustments, and monitoring for side effects like gastrointestinal issues or, in rare cases, pancreatitis.

Concerns Regarding Quality and Use

Key concerns include:

Quality and manufacturing variability: Semaglutide is a complex peptide, and variations in production, storage, or delivery methods can impact efficacy and safety.

Cold-chain and storage issues: Maintaining the required 2-8°C temperature across India's varied healthcare environments is challenging, and any breaks in the cold chain could diminish drug effectiveness.

Regulatory burden: With over 40 companies entering the market, ensuring consistent quality and reliability will stretch regulatory resources.

Inadequate physician training: Many prescribers may lack experience with GLP-1 receptor agonists, particularly in dose management and patient selection.

Pharmaceutical promotion vs. scientific education: Aggressive marketing may outpace unbiased medical education, especially in smaller healthcare facilities.

Indiscriminate or cosmetic use: There is a risk of semaglutide being misused for rapid weight loss without proper medical oversight.

Adverse effects and monitoring gaps: Side effects such as gastrointestinal issues and pancreatitis require proper counseling and follow-up, which may be lacking in routine practice.

The greatest benefits are likely to be seen in:

Patients with Type 2 diabetes and overweight/obesity

Individuals with poor glycemic control despite standard treatments

Patients at high cardiovascular risk or those who have experienced heart attacks or strokes

Individuals with metabolic syndrome or abdominal obesity

Selected patients with chronic kidney disease

People with obstructive sleep apnea

Individuals with severe fatty liver disease

Dr. Misra stated that semaglutide offers multifaceted benefits, including glucose reduction, weight loss, and cardiometabolic protection for these groups.

Who Should Avoid Semaglutide?

Semaglutide should be avoided or used with caution in:

Patients with a history of medullary thyroid carcinoma

Individuals with a history of pancreatitis

Those with severe gastrointestinal disorders (e.g., gastroparesis)

Pregnant or breastfeeding women

Patients with Type 1 diabetes

Patients with severe diabetic eye complications (use with caution)

Individuals seeking weight loss purely for cosmetic reasons without medical justification.